CNS Pharma regains Nasdaq bid price compliance; still faces equity rule delisting risk

CNS Pharmaceuticals, Inc.

Received Nasdaq letter on July 5, 2024 confirming bid price compliance (closing bid >=$1.00 for 20 consecutive business days through July 3).
Previously granted extension until July 15, 2024 to demonstrate compliance with both Bid Price and Equity Rules.
Company still not compliant with $2,500,000 stockholders' equity requirement (Nasdaq Listing Rule 5550(b)); further updates expected.
Delisting risk remains if equity compliance not demonstrated by deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.